Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC.JUNS · Entity 8326 | Director · Chief Scientific Officer | June 02, 2025 | July 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
JUPITER NEUROSCIENCES, INC.
Report date June 02, 2025 · Filed July 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,995,077 |
Ending reported balance
After 2026-03-02 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2025-06-02 · Exercise / conversion · Acquired 389,793 · Balance 2,370,675 F1: These securities convert into common stock on a one-for-one basis. Row 2 · 2025-06-02 · Exercise / conversion · Acquired 399,402 · Balance 2,770,077 F1: These securities convert into common stock on a one-for-one basis. Row 3 · 2026-03-02 · Exercise / conversion · Acquired 225,000 · Balance 2,995,077 F3: The shares underlying this option vested 100% on January 1, 2016 under the Company's 2016 Equity Incentive Plan. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2033-12-17 | Direct | 0 |
Reported balance
After 2025-06-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-06-02 · Exercise / conversion · Disposed 389,793 · Balance 0 F1: These securities convert into common stock on a one-for-one basis. F2: These awards vested on the expiration of the lock-up period for the Issuer's initial public offering. |
| Restricted Stock AwardSEC Table II · derivative / convertible security · Expires 2032-07-20 | Direct | 0 |
Reported balance
After 2025-06-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-06-02 · Exercise / conversion · Disposed 399,402 · Balance 0 F1: These securities convert into common stock on a one-for-one basis. F2: These awards vested on the expiration of the lock-up period for the Issuer's initial public offering. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.01 · Expires 2026-03-15 | Direct | 0 |
Reported balance
After 2026-03-02 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-03-02 · Exercise / conversion · Disposed 225,000 · Balance 0 F3: The shares underlying this option vested 100% on January 1, 2016 under the Company's 2016 Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities convert into common stock on a one-for-one basis.
F2: These awards vested on the expiration of the lock-up period for the Issuer's initial public offering.
F3: The shares underlying this option vested 100% on January 1, 2016 under the Company's 2016 Equity Incentive Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 02, 2026 Filed Jun 5, 2026 01:00 UTC | JUPITER NEUROSCIENCES, INC. JUNS · Entity 8326 | GrantStock Option · Derivative | 259,231 | $0.00 Strike: $0.28 | $0.00 |
DisclosureSEC source: 0001493152-26-027361 · ownership.xml · derivative · entry 1 Hayward Marshall A. · CIK 0001891872 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 259,231 Underlying: Common Stock · 259,231 shares Expires 2036-06-02 F1 · derivative.exercise_date: 259,231 options were granted under the Issuer's 2025 Equity Incentive Plan as a discretionary bonus for services rendered during fiscal 2025. The options vest over three years commencing from September 2, 2026 in equal quarterly installments subject to continued employment through each vesting date. Read SEC document |
| March 02, 2026 Filed Jul 13, 2026 20:00 UTC | JUPITER NEUROSCIENCES, INC. JUNS · Entity 8326 | Exercise / conversionStock Option (right to buy) · Derivative | 225,000 | $0.00 Strike: $0.01 | $0.00 |
DisclosureSEC source: 0001493152-26-033015 · ownership.xml · derivative · entry 6 Hayward Marshall A. · CIK 0001891872 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 225,000 shares Expires 2026-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares underlying this option vested 100% on January 1, 2016 under the Company's 2016 Equity Incentive Plan. Read SEC document |
| March 02, 2026 Filed Jul 13, 2026 20:00 UTC | JUPITER NEUROSCIENCES, INC. JUNS · Entity 8326 | Exercise / conversionCommon Stock | 225,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-26-033015 · ownership.xml · nonDerivative · entry 3 Hayward Marshall A. · CIK 0001891872 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,995,077 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The shares underlying this option vested 100% on January 1, 2016 under the Company's 2016 Equity Incentive Plan. Read SEC document |
| June 02, 2025 Filed Jul 13, 2026 20:00 UTC | JUPITER NEUROSCIENCES, INC. JUNS · Entity 8326 | Exercise / conversionRestricted Stock Award · Derivative | 399,402 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-033015 · ownership.xml · derivative · entry 5 Hayward Marshall A. · CIK 0001891872 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 399,402 shares Expires 2032-07-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These securities convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: These awards vested on the expiration of the lock-up period for the Issuer's initial public offering. Read SEC document |
| June 02, 2025 Filed Jul 13, 2026 20:00 UTC | JUPITER NEUROSCIENCES, INC. JUNS · Entity 8326 | Exercise / conversionRestricted Stock Units · Derivative | 389,793 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-033015 · ownership.xml · derivative · entry 4 Hayward Marshall A. · CIK 0001891872 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 389,793 shares Expires 2033-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These securities convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: These awards vested on the expiration of the lock-up period for the Issuer's initial public offering. Read SEC document |
| June 02, 2025 Filed Jul 13, 2026 20:00 UTC | JUPITER NEUROSCIENCES, INC. JUNS · Entity 8326 | Exercise / conversionCommon Stock | 399,402 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-26-033015 · ownership.xml · nonDerivative · entry 2 Hayward Marshall A. · CIK 0001891872 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,770,077 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These securities convert into common stock on a one-for-one basis. Read SEC document |
| June 02, 2025 Filed Jul 13, 2026 20:00 UTC | JUPITER NEUROSCIENCES, INC. JUNS · Entity 8326 | Exercise / conversionCommon Stock | 389,793 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-26-033015 · ownership.xml · nonDerivative · entry 1 Hayward Marshall A. · CIK 0001891872 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,370,675 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These securities convert into common stock on a one-for-one basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.